您现在的位置：肿瘤新网 >> 乳腺癌 >> 研究进展

美国教授发现能预测乳腺癌进展的最新标记物

来源：百济药房药讯作者：百济动态发布时间：2007-12-3 16:19:00

美国辛辛那提大学教授发现能预测乳腺癌进展的分子标记物——“osteopontin-c”（骨桥蛋白-C），“osteopontin-c”在正常组织中不表达，能更准确地预测乳腺癌的进展和远处转移。这项新的发现将可能改变乳腺癌患者的治疗决策，防止患者做不必要或太过激进的治疗。

目前，病理医生诊断乳腺癌时，需要观察预示乳腺癌生长的三大标志物——雌激素受体(ER)、孕激素受体(PR)和HER2，根据这三者的水平来做出判断。

“问题是雌激素受体(ER)、孕激素受体(PR)和HER2也会在正常的乳腺组织中被检测到，”来自美国辛辛那提大学药学院的教授Georg Weber, M.D., Ph.D.说，“另外，它们是细胞表面分子，会促进细胞生长，所以不一定能很好地预测肿瘤的转移。”

Weber教授和他的团队对178名对象（包含乳腺癌患者和正常人）进行了为期2年的跟踪研究，结果表明，在乳腺癌患者中，osteopontin-c阳性率比其他三大标记物要高。其中，78%的乳腺癌和36%的癌周组织中存在osteopontin-c，而在所有正常组织中未检测到osteopontin-c；在56例乳腺癌患者中，雌激素受体(ER)的阳性率为20/56，孕激素受体(PR)的阳性率为19/56，HER2的阳性率为26/56。

这项发现具有重要意义，假设知道患者体内存在“osteopontin-c”，就可以对患者采取手术、内分泌治疗和化疗等较为激进的治疗措施；反之，如果在早期诊断中发现患者体内不存在“osteopontin-c”，就没必要对患者采取这些较为激进的治疗措施，而采用一般的保守治疗就行了，因为乳腺癌发生转移的几率比前者更小些。（百济编译 www.cancerotc.cn）

Researchers have identified a molecule that may be more accurate than existing biological signposts used to predict which breast cancers will develop into advanced forms of the disease.

Detailed in an online edition of the International Journal of Cancer,the discovery could one day influence therapy decisions and prevent patients from unnecessarily undergoing aggressive cancer treatments.

When diagnosing breast cancer, pathologists currently look for elevated levels of three standard molecules known to make tumors grow in the breast.

These molecules—estrogen receptor (ER), progesterone receptor (PR) and HER2—are used as “biomarkers”for diagnosis and individually detect only a fraction of breast cancers.

“The problem with these biomarkers is that many of them are present at some level in the normal breast,”says Georg Weber, M.D., Ph.D., lead investigator of the new study and associate professor of pharmacy at the University of Cincinnati. “In addition, they are surface molecules that support growth so they are not necessarily a good predictor of tumor metastasis.”

Weber and his team have identified a molecule, osteopontin-c, that is absent from the normal breast and appears to more accurately predict breast cancer that will become metastatic and spread to distant organs from the original tumor site.In normal levels, osteopontin is a protein used by the immune system to help cells move and migrate. There are three forms of osteopontin—a, b and c—which are formed by splicing, or “cutting and pasting,” ribonucleic acid (RNA) molecules to make variations of the original gene. Osteopontin-a is the normal form that helps with immune functions. Little is known about osteopontin-b, but if present, its levels are very low. Osteopontin-c, the molecule Weber and his team discovered, is a good biomarker of breast cancer.

In a two-year evaluation of 178 breast tumors, normal and abnormal tissue samples, they found that osteopontin-c was present in 78 percent of cancers and in 36 percent of the surrounding tissues. It was not detected at all in normal tissues.

In 56 breast cancers, 20 were positive and 36 were negative for estrogen receptor, 19 were positive and 37 were negative for progesterone receptor, and 26 were positive for HER2 with 30 negative.

“Osteopontin-c was present in a substantially higher number of breast cancers than the three biomarkers traditionally used to diagnose breast cancer,” says Weber. “We also found that the cancers containing osteopontin-c correlated with a higher tumor grade, meaning they were more likely to become aggressive cancer.”

“If we know that this molecule is not present in a patient with breast cancer, it’s more likely that we can treat them with conservative therapy rather than breast surgery, hormone therapy or chemotherapy because we know it’s less likely to metastasize,” he adds. “On the other hand, if we know that a patient has this molecule early in their diagnosis,we can treat it more aggressively because we know their cancer is likely to become invasive.”

The study was funded by grants from U.S. Department of Defense Breast Cancer Program and the UC cancer research program. The tissue procurement was supported by a grant from the National Institutes of Health.

Collaborators include UC’s Mana Mirza and Elizabeth Shaughnessy, M.D., John Hurley, Kristie Vanpatten and Gary Pestano of Ventana Medical Systems in Tucson, Ariz., as well as Bin He, M.D., of the North Shore Medical Center in Salem, Mass.

参考文献（略）

您现在的位置：肿瘤新网 >> 乳腺癌 >> 研究进展

美国教授发现能预测乳腺癌进展的最新标记物

相关病种药品：乳腺癌

相关文章

相关上市新药

温馨提示

栏目导航

服务特色

药品目录

通用栏目导航

热点专题

您现在的位置： 肿瘤新网 >> 乳腺癌 >> 研究进展

美国教授发现能预测乳腺癌进展的最新标记物

相关病种药品： 乳腺癌

相关文章

相关上市新药

温馨提示

栏目导航

服务特色

药品目录

通用栏目导航

热点专题

您现在的位置：肿瘤新网 >> 乳腺癌 >> 研究进展

相关病种药品：乳腺癌